We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
CRISPR Therapeutics AG (CRSP - Free Report) closed at $45.15 in the latest trading session, marking a -1.25% move from the prior day. This change lagged the S&P 500's daily gain of 1.68%. Elsewhere, the Dow gained 1.06%, while the tech-heavy Nasdaq lost 1.7%.
Coming into today, shares of the company had lost 11.24% in the past month. In that same time, the Medical sector lost 5.62%, while the S&P 500 lost 6.68%.
Investors will be hoping for strength from CRISPR Therapeutics AG as it approaches its next earnings release. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.95 per share, which would represent year-over-year growth of 15.95%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $12.68 million, up 1248.51% from the year-ago period.
CRSP's full-year Zacks Consensus Estimates are calling for earnings of -$7.54 per share and revenue of $136.88 million. These results would represent year-over-year changes of +9.81% and +11325.89%, respectively.
Investors might also notice recent changes to analyst estimates for CRISPR Therapeutics AG. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 8.14% higher within the past month. CRISPR Therapeutics AG is holding a Zacks Rank of #2 (Buy) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 99, which puts it in the top 40% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
CRISPR Therapeutics AG (CRSP - Free Report) closed at $45.15 in the latest trading session, marking a -1.25% move from the prior day. This change lagged the S&P 500's daily gain of 1.68%. Elsewhere, the Dow gained 1.06%, while the tech-heavy Nasdaq lost 1.7%.
Coming into today, shares of the company had lost 11.24% in the past month. In that same time, the Medical sector lost 5.62%, while the S&P 500 lost 6.68%.
Investors will be hoping for strength from CRISPR Therapeutics AG as it approaches its next earnings release. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.95 per share, which would represent year-over-year growth of 15.95%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $12.68 million, up 1248.51% from the year-ago period.
CRSP's full-year Zacks Consensus Estimates are calling for earnings of -$7.54 per share and revenue of $136.88 million. These results would represent year-over-year changes of +9.81% and +11325.89%, respectively.
Investors might also notice recent changes to analyst estimates for CRISPR Therapeutics AG. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 8.14% higher within the past month. CRISPR Therapeutics AG is holding a Zacks Rank of #2 (Buy) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 99, which puts it in the top 40% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.